United States
                     Securities and Exchange Commission
                            Washington, DC 20549

                              FORM 10-QSB/A-1

               Quarterly Report Under Section 13 or 15(d) of
                    the Securities Exchange Act of 1934

For the Quarter Ended                             Commission File Number
September 30, 2000                                           0-30935

                              NOVAMEX USA LTD.
           (Exact name of registrant as specified in its charter)

                                   OREGON
       (State or other jurisdiction of incorporation or organization)

                                 98-0198290
                    (I.R.S. Employer Identification No.)

                         360 rue Franquet, Suite 10
                         Sainte-Foy, Quebec, Canada
                  (Address of principal executive offices)

                               (418) 652-9001
            (Registrant's telephone number, including area code)

        Securities registered pursuant to Section 12 (b) of the Act:

                                    None

     Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past 90 days.

               Yes     X  No
          -----     -----

State the number of shares outstanding of each of the registrants classes
of common equity, as of the latest practicable date.

     Common stock, par value $.001; 10,500,000 shares outstanding as of
September 10, 2001


<PAGE>
ITEM   1. FINANCIAL STATEMENTS
NOVAMEX USA LTD AND SUBSIDIARY
(A DEVELOPMENT STAGE COMPANY)
---------------------------------------------------------------------------
CONSOLIDATED BALANCE SHEET (in U.S. Dollars)
---------------------------------------------------------------------------
                    ASSETS
<Table>
<Caption>
                                                 September 30     June 30
                                                     2000          2000
                                                 ------------  ------------
<S>                                             <C>           <C>
CURRENT ASSETS

  Cash                                            $    5,711    $   12,929
  Accounts receivable                                 18,964        17,952
  Advances to a related company                            -           250
  Advances to directors non-interest
   bearing and without specific terms of
   repayment                                               -         7,798
  Research and development tax credits
   receivable                                          5,611         5,698
  Prepaid expenses                                       482           978
                                                 ------------  ------------
                                                      30,768        45,605

EQUIPMENT - net of amortization                       19,325        20,656

  Proprietary technology                                   1             1
                                                 ------------  ------------
                                                 $    50,094   $    66,262
                                                 ============  ============
                    LIABILITIES
CURRENT LIABILITIES

  Accounts payable and accrued liabilities      $    288,339  $    286,668
  Due to an individual, non-interest bearing
   and without specific methods of repayment          64,251        65,246
                                                 ------------  ------------
                                                     352,590       351,914

DEFERRED INCOME TAXES                                  3,578         3,634
                                                 ------------  ------------
                                                     356,168       355,548
                    DEFICIENCY IN ASSETS
CAPITAL STOCK

  Preferred stock, $0.10 par value, 1,000,000
   shares authorized voting and participating,
   no shares outstanding:                                  -             -
  Common stock, no par value, 100,000,000
   shares authorized, voting and participating,
   10,500,000, outstanding and paid                      332           332

DEFICIT ACCUMULATED DURING THE DEVELOPMENT STAGE    (306,701)     (288,072)

ACCUMULATED OTHER COMPREHENSIVE INCOME                   295        (1,546)
                                                 ------------  ------------
                                                    (306,074)     (289,286)
                                                 ------------  ------------
                                                 $    50,094   $    66,262
                                                 ============  ============
</Table>
NOVAMEX USA LTD AND SUBSIDIARY
(A DEVELOPMENT STAGE COMPANY)
---------------------------------------------------------------------------
CONSOLIDATED STATEMENT OF INCOME
AND DEFICIT (in U.S. dollars)
---------------------------------------------------------------------------
<Table>
<Caption>
                                        From July                From July
                              Three      31, 1996      Three      31, 1996
                              months   (inception)     months   (inception)
                              ended      through       ended      through
                            September   September    September   September
                               30           30          30           30
                           ------------------------------------------------
                              2000         2000        1999         1999
                          -----------  ----------- -----------  -----------
                           (3 months)               (3 months)
<S>                      <C>          <C>         <C>          <C>
EXPENSES
  Operating               $   16,704   $  136,024  $    2,692   $   15,828
  Less research and
   development tax
   credits                         -       (5,698)          -            -
  Selling                          -       19,536       3,689       12,659
  Administrative               9,285      400,959         932      100,483
  Financial                      101        5,430       1,244        3,231
  Loss (gain) on
   foreign exchange           (2,819)      (3,567)       (121)         113
                          -----------  ----------- -----------  -----------
                              23,271      552,684       8,706      132,314

LESS revenues realized
  during development
  stage                        4,642      250,170           -          447
                          -----------  ----------- -----------  -----------
LOSS BEFORE INCOME TAXES      18,629      302,514       8,706      131,867

INCOME TAXES
  Current (recovered)              -          (98)          -          (98)
  Deferred                         -        4,285      (1,346)     (26,441)
                          -----------  ----------- -----------  -----------
NET LOSS                      18,629      306,701       7,360      105,328

DEFICIT AT BEGINNING
OF PERIOD                    288,072            -      97,968            -
                          -----------  ----------- -----------  -----------

DEFICIT AT END OF PERIOD  $  306,701   $  306,701  $  105,328   $  105,328
                          ===========  =========== ===========  ===========

Loss per common share          0.002         0.03       0.001         0.01
                          ===========  =========== ===========  ===========

Weighted average number
of common shares
outstanding               10,500,000   10,500,000  10,500,000   10,500,000
                          ===========  =========== ===========  ===========

</Table>

NOVAMEX USA LTD AND SUBSIDIARY
(A DEVELOPMENT STAGE COMPANY)
---------------------------------------------------------------------------
CONSOLIDATED STATEMENT OF CASH FLOWS (in U.S. dollars)
---------------------------------------------------------------------------
<Table>
<Caption>
                                                  Three months period ended
                                                        September 30,
                                                 --------------------------
                                                     2000          1999
                                                 ------------  ------------
<S>                                             <C>           <C>
                                                  (3 months)    (3 months)
CASH PROVIDED BY (USED IN)

OPERATIONS

  Net loss                                         $ (18,629)     $ (7,360)

  Items not involving cash
  Adjustments to reconcile net loss to net
    cash used in operating activities
  Amortization                                         1,032             -
  Deferred income taxes                                    -        (1,346)
                                                 ------------  ------------
                                                     (17,597)       (8,706)
  Change in non cash operating working capital:
  Accounts receivable, advances to a related
    company and directors                              6,735          (539)
  Income taxes receivable                                  -            99
  Prepaid expenses                                       489             -
  Accounts payable and accrued liabilities             4,193         1,397
  Advances from directors                                  -          (686)
  Advances from an individual                           (898)        2,685
                                                 ------------  ------------
  Net cash used in operating activities               (7,078)       (5,750)
                                                 ------------  ------------
INVESTING

  Additions of equipment                                   -          (493)
                                                 ------------  ------------
  Net cash used in investing activities                    -          (493)

FINANCING

  Change in bank loan                                      -         9,992
                                                 ------------  ------------
  Net cash provided by financing activities                -         9,992
                                                 ------------  ------------
CASH INCREASE (DECREASE)                              (7,078)        3,749

CURRENCY TRANSLATION ADJUSTMENT ON CASH                 (140)           20

CASH AT BEGINNING OF PERIOD                           12,929         2,803
                                                 ------------  ------------
CASH AT END OF PERIOD                            $     5,711   $     6,572
                                                 ============  ============

</Table>


NOVAMEX USA LTD AND SUBSIDIARY
(A DEVELOPMENT STAGE COMPANY)
---------------------------------------------------------------------------

CONSOLIDATED STATEMENT OF OTHER
COMPREHENSIVE INCOME (in U.S. dollars)
---------------------------------------------------------------------------
<Table>
<Caption>
                                                        September 30,
                                                 --------------------------
                                                     2000          1999
                                                 ------------  ------------
                                                  (3 months)    (3 months)
<S>                                             <C>           <C>

BALANCE AT BEGINNING OF PERIOD                      $ (1,546)     $ (2,626)

EFFECT OF TRANSLATION DURING PERIOD                    1,841           722
                                                 ------------  ------------
BALANCE AT END OF PERIOD                         $       295   $    (1,904)
                                                 ============  ============


</Table>


ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL STATEMENTS

     This Form 10-QSB contains certain forward-looking statements.  For
this purpose any statements contained in this Form 10-QSB that are not
statements of historical fact may be deemed to be forward-looking
statements.  Without limiting the foregoing, words such as "may," "will,"
"expect," "believe," "anticipate," "estimate" or "continue" or comparable
terminology are intended to identify forward-looking statements.  These
statements by their nature involve substantial risks and uncertainties, and
actual results may differ materially depending on a variety of factors.

General

     Novamex USA Ltd. (the "Company"), was originally incorporated in the
state of Oregon on February 12, 1991 under the name International Business
Development Ltd. The Company was organized and authorized to pursue any
lawful purpose or purposes. The Company amended its Articles of
Incorporation on June 23, 1998, changing its name to Novamex USA Ltd. The
Company has had limited revenues and is considered to be a "development
stage company."

     The Company operates in the biotechnology industry.  The Company
develops and manufactures detection kits mainly to non-clinical industry
segments including the agri-food  and veterinary segments.  Non-clinical
methods of testing and detection include those that are not intended to be
used for establishing a clinical diagnosis.  These non-clinical methods are
usually used in house for self control purposes and are most prominently
used in the food industry to better control microbial contamination during
processing.   To be useful, however, these methods must meet acceptable
performance criteria.

     The Company uses antigen-antibody reaction technology and employ rapid
diagnostic methods in their detection tests.  The Company has developed
unique testing methods in which any detectible reaction takes place
entirely inside a plastic cassette. Their tests also have other benefits of
the rapid diagnostic methods such as no incubation or washing steps.  Tests
developed by the Company produce results in approximately fifteen minutes.

     Test results are read visually using a colorimetric reaction.
Moreover, these methods do not need any sophisticated equipment and may be
carried out as field tests by workers having no laboratory training.  The
average cost for a test is between U.S. $4.50 and $7 per sample. The
Company has developed timely, affordable tests that do not compromise
accuracy.  The Company's evaluation  results have established 99.4%
accuracy rating on many of its detection tests, although such accuracy
ratings have been established by the Company in its controlled environment.

     The tests have a shelf life of approximately 14 months when stored at
four degrees Celsius (4 degrees C).  Each test uses enzymes or colored
particles coupled with specific antibodies.  Any reaction between
antibodies and antigens are revealed by adding a chromogenic substance
(pigment producing micro-organism) to the sample.  If a reaction has taken
place, or in other words the test is positive, the test will yield a blue
color that is visible to the naked eye.

     The general hygiene kit is the only test kit currently commercialized
and it has produced limited revenue since September of 1999.  This kit does
not require any special equipment and can be performed by anyone with
minimal training.  These tests have advantages over other popular hygiene
tests that are often costly, difficult to interpret and may give variable
or inconsistent results.  This test currently represents the largest source
of revenue for the Company.  The Company is currently developing
approximately six other test kits and has plans to research and develop
three additional kits.

Liquidity and Capital Resources

     At September 30, 2000, the Company had cash of $5,711 on hand.  The
Company has limited capital resources and is substantially dependent upon
sales proceeds from the Company's general hygiene test kit to meet its
capital requirements. Sales from the hygiene test kit are the only source of
revenue and currently will not provide sufficient capital through the
development stage. As a result, the Company may need to seek additional
capital through traditional bank loans, a private offering of common stock or
another form of debt or equity financing.  If the Company is not successful
in raising sufficient capital through any of the aforementioned options, the
ability of the Company to meet its financial obligations in a timely manner
or to remain in business is doubtful.

Results of Operations

     Comparison of the three months ended September 30, 2000 and the three
     months ended September 30, 1999.

     During the first three months of fiscal 2000, the Company's net cash
used in operations was $7,078 compared to cash used in operations of $5,570
during the first three months of fiscal 1999. The first quarter 2000
operating activities cash utilization increase is primarily the result of an
operating loss of $18,629 compared to an operating loss of $7,360 for the
three months ended September 30, 1999.

     Accounts receivable increased to $18,964 in the first quarter of 2000
compared to $17,952 in the same quarter of 1999.  The Company realized
revenues in the amount of $4,642 in the first quarter of fiscal 2000 compared
to no revenues in the same quarter of 1999.  The accounts receivable increase
and all revenue realized was generated from sales of the Company's general
hygiene test kit. The Company expects to continue to utilize any revenues
generated by the Company to continue its research and development efforts.

     Administrative expenses increased from $932 in 1999 to $9,285 for the
first quarter of 2000 while operating expenses increased to $16,704 in the
first quarter 2000 compared to $2,962 in the same quarter of 1999. The total
deficit from inception through the end of the first quarter of 2000 was
$306,701 compared to $105,328 for the same period in 1999.  These increases
were due to accelerated efforts in research and development activities.

     The Company expects all of the trends reported herein to continue at a
similar pace through the next twelve months.

PART II - OTHER INFORMATION

Item 1.  Legal Proceedings

     None.

Item 2.  Changes in Securities

     No instruments defining the rights of the holders of any class of
registered securities have been materially modified, limited or qualified.

     Since the Company's last report for the year ended June 30, 2000, the
Company has not issued or sold any securities which are not registered under
the Securities Act of 1933.

Item 3.  Defaults upon Senior Securities

     None

Item 4.  Submission of Matters to a Vote of Security Holders

     None

Item 5.  Other Information


Item 6.  Exhibits and Reports on Form 8-K

     (A)  Reports on Form 8-K

     No reports on Form 8-K were filed or required to be filed during the
quarter ended September 30, 2000.

     (B)  Exhibits.  The following exhibits are included as part of this
report:
               None.




                                 SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this to be signed on its behalf by the undersigned
thereunto duly authorized.

                                   Novamex USA, Ltd.

September 10, 2001                 By: /s/ Karim Menassa
                                   --------------------------------
                                   President


September 10, 2001                 By: Jean-Francois Welch
                                   -------------------------------
                                   Secretary